Theraflu Disclaimer Exceeds NAD Expectations For Consumer Comprehension
This article was originally published in The Tan Sheet
Executive Summary
Novartis’ substantiation fails to support onset of action claims for Theraflu Multi-Symptom Severe Cold in TV, online and print ads, according to a NAD review of a challenge by Pfizer. NAD says a disclaimer in the ads contradicted rather than limited an onset of action claim, and likely was missed by consumers anyway.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.